1
|
Erk N, Vural Ö, Bouali W, Ayse Genc A, Gnanasekaran L, Karimi-Maleh H. Smart and sensitive nanomaterial-based electrochemical sensor for the determination of a poly (ADP-ribose) polymerase (PARP) inhibitor anticancer agent. ENVIRONMENTAL RESEARCH 2023; 238:117082. [PMID: 37699471 DOI: 10.1016/j.envres.2023.117082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/23/2023] [Revised: 08/31/2023] [Accepted: 09/05/2023] [Indexed: 09/14/2023]
Abstract
In this research, we propose a novel approach for constructing a sensitive and selective electrochemical sensor utilizing high-quality multi-walled carbon nanotubes functionalized with amino groups (MWCNT-NH2) for the detection of Talazoparib (TLZ), a poly (ADP-ribose) polymerase (PARP) enzyme inhibitor, in real samples. The MWCNT-NH2-based sensor exhibited remarkable performance characteristics, including excellent repeatability, reproducibility, and high selectivity against various interferences. Under optimized conditions, the sensor demonstrated a wide linear concentration range of 1.0-5.0 μM, with a low limit of detection (LOD) of 0.201 μM. Substantiated by rigorous analysis of pharmaceutical and biological matrices, our methodology emerges as a paragon of reliability, boasting recovery rates within the satisfactory bracket of 96.38-105.25%. The successful application of the MWCNT-NH2-based sensor in practical sample analysis highlights its potential for implementation in clinical and pharmaceutical settings. This research not only advances the application of MWCNT-NH2 in electrochemical sensing but also opens new avenues for the development and monitoring of innovative anticancer treatments. The insights gained from our study have far-reaching implications, pointing toward a future where precision and innovation converge to improve patient care and treatment outcomes.
Collapse
Affiliation(s)
- Nevin Erk
- Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06560, Ankara, Turkey.
| | - Özgül Vural
- Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06560, Ankara, Turkey; Ankara University, The Graduate School of the Health Sciences, 06110, Ankara, Turkey
| | - Wiem Bouali
- Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06560, Ankara, Turkey; Ankara University, The Graduate School of the Health Sciences, 06110, Ankara, Turkey
| | - Asena Ayse Genc
- Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06560, Ankara, Turkey; Ankara University, The Graduate School of the Health Sciences, 06110, Ankara, Turkey
| | - Lalitha Gnanasekaran
- Institueto de Alta Investigacion, Universidad de Tarapaca, Arica, 1000000, Chile
| | - Hassan Karimi-Maleh
- The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, PR China; School of Resources and Environment, University of Electronic Science and Technology of China, P.O. Box 611731, Xiyuan Ave, Chengdu, PR China; School of Engineering, Lebanese American University, Byblos, Lebanon; Ankara University, Faculty of Pharmacy, Department of Analytical Chemistry, 06560, Ankara, Turkey.
| |
Collapse
|
2
|
Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition. Br J Cancer 2021; 124:1260-1274. [PMID: 33473172 PMCID: PMC8007595 DOI: 10.1038/s41416-020-01238-0] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Revised: 11/21/2020] [Accepted: 12/11/2020] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Poly(ADP-ribose) polymerase inhibitors (PARPi) target tumours defective in homologous recombination (HR). Most BRCA-wild-type (WT) HR-proficient breast cancers are intrinsically resistant to PARP inhibitors, e.g., talazoparib. We evaluated the role of autophagy in this de novo resistance and determined the underlying mechanism to overcome this. METHODS Autophagosome formation and autophagic flux were assessed by evaluating endogenous LC3-II levels and ectopic expression of EGFP-LC3 and mRFP-EGFP-LC3 in breast cancer cells. Autophagy-defective cells were generated by genetic depletion of BECN1, ATG5, p62/SQSTM1 and LAMP1 by using CRISPR-Cas9 double nickase system. The response of PARPi was evaluated in autophagy-proficient and -defective breast cancer cells and in xenograft SCID-mice model. RESULTS Pro-survival autophagy was significantly enhanced upon talazoparib treatment in BRCA-WT breast cancer cell lines. Autophagy-deficient cells were hypersensitive to talazoparib. Targeting autophagy synergistically enhanced the therapeutic efficacy of talazoparib in BRCA1-WT breast cancer cells in vitro and in vivo xenograft tumour mouse model. Mechanistically, autophagy inhibition by chloroquine promoted deleterious NHEJ mediated DSB-repair, leading to extensive genomic instability and mitotic catastrophe. CONCLUSIONS Autophagy confers de novo resistance to PARP inhibitor, talazoparib. Autophagy inhibition improves the therapeutic outcome of PARPi treatment in preclinical mice model, bearing HR-proficient breast tumours, warranting its usage in the clinical settings.
Collapse
|
3
|
Abbas G, Saadullah M, Rasul A, Shah S, Khan SM, Hanif M, Masood Ahmed M. Development and validation of high-performance liquid chromatography method for the simultaneous monitoring of pantoprazole sodium sesquihydrate and domperidone maleate in plasma and its application to pharmacokinetic study. ACTA CHROMATOGR 2020. [DOI: 10.1556/1326.2019.00525] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
A sensitive, inexpensive high-performance liquid chromatography–ultraviolet detection (HPLC–UV) method has been developed and validated for the simultaneous monitoring of pantoprazole sodium sesquihydrate (PSS) and domperidone maleate (DM) in rabbit plasma on a C18 column with UV detection at 285 nm. Box–Behnken design was used with 3 independent variables, namely, flow rate (X1), mobile phase composition (X2), and phosphate buffer pH (X3), which were used to design mathematical models. Response surface design was applied to optimize the dependent variables, i.e., retention time (Y1 and Y2) and percentage recoveries (Y3 and Y4) of PSS and DM. The method was sensitive and reproducible over 1.562 to 25 μg/mL. The effect of the quadratic outcome of flow rate, mobile phase composition, and buffer pH on retention time (p ˂ 0.001) and percentage recoveries of PSS and DM (p = 0.0016) were significant. The regression values obtained from analytical curve of PSS and DM were 0.999 and 0.9994, respectively. The percentage recoveries of PSS and DM were ranged from 94.5 to 100.41% and 94.77 to 100.31%, respectively. The developed method was applied for studying the pharmacokinetics of PSS and DM. The Cmax of test and reference formulations were 48.06 ± 0.347 μg/mL and 46.31 ± 0.398 μg/mL for PSS, and 15.11 ± 1.608 μg/mL and 12.06 ± 1.234 μg/mL for DM, respectively.
Collapse
Affiliation(s)
- Ghulam Abbas
- 1 Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan
- 2 Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
| | - Malik Saadullah
- 2 Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
| | - Akhtar Rasul
- 2 Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
| | - Shahid Shah
- 2 Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
| | - Sajid Mehmood Khan
- 3 Faculty of Pharmacy and Alternative Medicine, The Islamia University, Bahawalpur, Pakistan
| | - Muhammad Hanif
- 1 Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan
| | | |
Collapse
|
4
|
Bruin MAC, de Vries N, Lucas L, Rosing H, Huitema ADR, Beijnen JH. Development and validation of an integrated LC-MS/MS assay for therapeutic drug monitoring of five PARP-inhibitors. J Chromatogr B Analyt Technol Biomed Life Sci 2020; 1138:121925. [PMID: 31915109 DOI: 10.1016/j.jchromb.2019.121925] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 11/29/2019] [Accepted: 12/02/2019] [Indexed: 12/29/2022]
Abstract
An liquid chromatography-mass spectrometry (LC-MS/MS) assay was developed for the combined analysis of the five poly (ADP-ribose) polymerase (PARP) inhibitors niraparib, olaparib, rucaparib talazoparib and veliparib. A simple and fast sample pre-treatment method was used by protein precipitating of plasma samples with acetonitrile and dilution of the supernatant with formic acid (0.1% v/v in water). This was followed by chromatographic separation on a reversed-phase UPLC BEH C18 column and detection with a triple quadrupole mass spectrometer operating in the positive mode. A simplified validation procedure specifically designed for bioanalytical methods for clinical therapeutic drug monitoring (TDM) purposes, was applied. This included assessment of the calibration model, accuracy and precision, lower limit of quantification (LLOQ), specificity and selectivity, carry-over and stability. The validated range was 30-3000 ng/mL for niraparib, 100-10,000 ng/mL for olaparib, 50-5000 ng/mL for rucaparib, 0.5-50 ng/mL for talazoparib and 50-5000 for veliparib. All results were within the criteria of the US Food and Drug Administration (FDA) guidance and European Medicines Agency (EMA) guidelines on method validation. The assay has been successfully implemented in our laboratory.
Collapse
Affiliation(s)
- M A C Bruin
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
| | - N de Vries
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - L Lucas
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - H Rosing
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - A D R Huitema
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands
| | - J H Beijnen
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands
| |
Collapse
|
5
|
Jain S, Jadav T, Sahu AK, Kalia K, Sengupta P. An Exploration of Advancement in Analytical Methodology for Quantification of Anticancer Drugs in Biomatrices. ANAL SCI 2019; 35:719-732. [PMID: 30905906 DOI: 10.2116/analsci.19r002] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Significant numbers of newer anticancer drugs are regularly entering into the market worldwide to fight against different types of cancers. Analytical methodologies are being developed to quantitate those molecules in a variety of matrices during their drug development stages. Selection of biological matrices for developing bioanalytical methods is based on the mechanism of action, site of action, site of metabolism and route of excretion of the drugs or their metabolites. In this review, we have described the current scenario and advancements in bioanalytical techniques for quantification of different anticancer drugs in a variety of biomatrices with a special emphasis on sample preparation techniques. We have discussed and summarized different bioanalytical aspects for anticancer drugs, which can give direction to the researcher for choosing appropriate techniques for their quantification needs.
Collapse
Affiliation(s)
- Sonali Jain
- National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad
| | - Tarang Jadav
- National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad
| | - Amit Kumar Sahu
- National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad
| | - Kiran Kalia
- National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad
| | - Pinaki Sengupta
- National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad
| |
Collapse
|
6
|
Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry. Pharmaceutics 2018; 10:pharmaceutics10040260. [PMID: 30513962 PMCID: PMC6321172 DOI: 10.3390/pharmaceutics10040260] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2018] [Revised: 11/26/2018] [Accepted: 11/26/2018] [Indexed: 12/20/2022] Open
Abstract
A simple and sensitive liquid chromatography⁻quadrupole-time-of-flight⁻mass spectrometric (LC-QTOF-MS) assay has been developed for the evaluation of drug metabolism and pharmacokinetics (PK) properties of vipadenant in rat, a selective A2a receptor antagonist as one of the novel immune checkpoint inhibitors. A simple protein precipitation method using acetonitrile was used for the sample preparation and the pre-treated samples were separated by a reverse-phase C18 column. The calibration curve was evaluated in the range of 3.02 ~ 2200 ng/mL and the quadratic regression (weighted 1/concentration) was used for the best fit of the curve with a correlation coefficient ≥0.997. The in vivo PK studies in rats showed that vipadenant bioavailability was 30.4 ± 8.9% with a low to moderate drug clearance. In addition, in vitro/in vivo metabolite profiles in rat were also explored. Five different metabolites were observed in our experimental conditions and the major metabolites were different between in vitro and in vivo conditions. As far as we know, there has been no report on the development of quantitative methods for its PK samples nor the identification of its metabolites since vipadenant was developed. Therefore, this paper would be very useful to better understand the pharmacokinetic and drug metabolism properties of vipadenant in rat as well as other species.
Collapse
|
7
|
Li D, Zhao G, Ai W, Li G, Si L, Huang J, Chen Y, Wu S. Simultaneous LC-MS/MS bioanalysis of etoposide and paclitaxel in mouse tissues and plasma after oral administration of self-microemulsifying drug-delivery systems. Biomed Chromatogr 2018; 32:e4192. [PMID: 29349799 DOI: 10.1002/bmc.4192] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Revised: 12/13/2017] [Accepted: 01/09/2018] [Indexed: 12/27/2022]
Affiliation(s)
- Dan Li
- Department of Pharmacy; Shenzhen University Genneral Hospital; Shenzhen Guangdong People' Republic of China
- Department of Pharmaceutics, School of Pharmacy, Tongji Medical College; Huazhong University of Science and Technology; Wuhan People' Republic of China
| | - Gang Zhao
- Department of Pharmaceutics, School of Pharmacy, Tongji Medical College; Huazhong University of Science and Technology; Wuhan People' Republic of China
- Institute of Pharmaceutical Research; Jianmin Pharmaceutical Group; Wuhan People' Republic of China
| | - Weipeng Ai
- Department of Pharmacy; Shenzhen University Genneral Hospital; Shenzhen Guangdong People' Republic of China
| | - Gao Li
- Department of Pharmaceutics, School of Pharmacy, Tongji Medical College; Huazhong University of Science and Technology; Wuhan People' Republic of China
| | - Luqin Si
- Department of Pharmaceutics, School of Pharmacy, Tongji Medical College; Huazhong University of Science and Technology; Wuhan People' Republic of China
| | - Jiangeng Huang
- Department of Pharmaceutics, School of Pharmacy, Tongji Medical College; Huazhong University of Science and Technology; Wuhan People' Republic of China
| | - Yunzhou Chen
- Department of Pharmacy, Tongji Hospital, Tongji Medical College; Huazhong University of Science and Technology; Wuhan People' Republic of China
| | - Sanlan Wu
- Department of Pharmacy, Union Hospital, Tongji Medical College; Huazhong University of Science and Technology; Wuhan People' Republic of China
| |
Collapse
|
8
|
Wang YT, Yuan B, Chen HD, Xu L, Tian YN, Zhang A, He JX, Miao ZH. Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression. Cancer Sci 2018; 109:821-831. [PMID: 29274141 PMCID: PMC5834817 DOI: 10.1111/cas.13477] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2017] [Revised: 12/07/2017] [Accepted: 12/18/2017] [Indexed: 12/19/2022] Open
Abstract
With increasing uses of poly(ADP‐ribose) polymerase (PARP) inhibitors (PARPi) for cancer therapy, understanding their resistance is becoming urgent. However, acquired PARPi resistance in the phosphatase and tensin homolog (PTEN)‐deficient background is poorly understood. We generated 3 PARPi‐resistant PTEN‐deficient glioblastoma U251 variants separately with olaparib (U251/OP), talazoparib (U251/TP) and simmiparib (U251/SP). These variants displayed consistent resistance (2.46‐71.78‐fold) to all 5 PARPi, including niraparib and rucaparib, and showed higher degrees of resistance to the PARPi to which the parental cells were more sensitive. The resistance was characteristic of fast emergence and high stability. However, the resistance acquirement did not cause an increasingly aggressive phenotype. The resistance was not correlated to various factors, including PTEN mutations. The PARPi‐treated variants produced less γH2AX and G2/M arrest. Consistently, loss of 53BP1 occurred in all variants and its compensation enhanced their sensitivity to PARPi by approximately 76%. The variants revealed slightly different cross‐resistance profiles to 13 non‐PARPi anticancer drugs. All were resistant to Ara‐C (6‐8‐fold) but showed differential resistance to 5‐fluorouracil, gemcitabine and paclitaxel. Almost no resistance was observed to the rest drugs, including cisplatin. SAMHD1 was overexpressed in all the variants and its knockout completely restored their sensitivity to Ara‐C but did not affect their PARPi sensitivity. The present study demonstrates a consistent resistance profile to PARPi and a unique cross‐resistance profile to non‐PARPi drugs in different PARPi‐resistant U251 cells and reveals 53BP1 loss and SAMHD1 overexpression as the primary mechanisms responsible for their resistance to PARPi and Ara‐C, respectively. These effects probably result from heritable gene change(s) caused by persistent PARPi exposure.
Collapse
Affiliation(s)
- Yu-Ting Wang
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Bo Yuan
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Hua-Dong Chen
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Lin Xu
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Yu-Nan Tian
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.,University of Chinese Academy of Sciences, Beijing, China
| | - Ao Zhang
- Department of Medicinal Chemistry, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Jin-Xue He
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| | - Ze-Hong Miao
- Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
| |
Collapse
|